Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Wanner

Showing results (531-540 of 666) with videos related to

Pageof 67
Sort By:
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 28, 2024
The safety of a low-protein diet in older adults with advanced chronic kidney diseaseKarin Windahl, Nicholas C Chesnaye, Gerd Faxén Irving, et al.
BMC Nephrology|September 4, 2016
International Network of Chronic Kidney Disease cohort studies (iNET-CKD): a global network of chronic kidney disease cohortsThomas Dienemann, Naohiko Fujii, Paula Orlandi, et al.
Journal of the American Society of Nephrology : JASN|January 9, 2015
Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D StudiesChristiane Drechsler, Graciela Delgado, Christoph Wanner, et al.
Kidney International|May 16, 2014
Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney diseaseEdwin M Spithoven, Anneke Kramer, Esther Meijer, et al.
Kidney Medicine|July 4, 2025
Predicting Hospitalization and Related Outcomes in Advanced Chronic Kidney Disease: A Systematic Review, External Validation, and Development StudyRoemer J Janse, Jet Milders, Joris I Rotmans, et al.
Molecular Genetics and Metabolism|December 3, 2009
A validated disease severity scoring system for Fabry diseaseEdward H Giannini, Atul B Mehta, Max J Hilz, et al.
Clinical Kidney Journal|July 5, 2021
Real-world safety and effectiveness of sucroferric oxyhydroxide for treatment of hyperphosphataemia in dialysis patients: a prospective observational studyMarc G Vervloet, Ioannis N Boletis, Angel L M de Francisco, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 11, 2024
Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trialHiddo J L Heerspink, Rajiv Agarwal, George L Bakris, et al.
Cardiovascular Diabetology|March 16, 2018
Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA<sup>®</sup>): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal riskJulio Rosenstock, Vlado Perkovic, John H Alexander, et al.
Journal of Medical Genetics|February 14, 2018
Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort studyMaarten Arends, Marieke Biegstraaten, Christoph Wanner, et al.
Pageof 67

Showing results (531-540 of 666) with videos related to

Sort By:
Pageof 67
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 28, 2024
The safety of a low-protein diet in older adults with advanced chronic kidney diseaseKarin Windahl, Nicholas C Chesnaye, Gerd Faxén Irving, et al.
BMC Nephrology|September 4, 2016
International Network of Chronic Kidney Disease cohort studies (iNET-CKD): a global network of chronic kidney disease cohortsThomas Dienemann, Naohiko Fujii, Paula Orlandi, et al.
Journal of the American Society of Nephrology : JASN|January 9, 2015
Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D StudiesChristiane Drechsler, Graciela Delgado, Christoph Wanner, et al.
Kidney International|May 16, 2014
Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney diseaseEdwin M Spithoven, Anneke Kramer, Esther Meijer, et al.
Kidney Medicine|July 4, 2025
Predicting Hospitalization and Related Outcomes in Advanced Chronic Kidney Disease: A Systematic Review, External Validation, and Development StudyRoemer J Janse, Jet Milders, Joris I Rotmans, et al.
Molecular Genetics and Metabolism|December 3, 2009
A validated disease severity scoring system for Fabry diseaseEdward H Giannini, Atul B Mehta, Max J Hilz, et al.
Clinical Kidney Journal|July 5, 2021
Real-world safety and effectiveness of sucroferric oxyhydroxide for treatment of hyperphosphataemia in dialysis patients: a prospective observational studyMarc G Vervloet, Ioannis N Boletis, Angel L M de Francisco, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 11, 2024
Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trialHiddo J L Heerspink, Rajiv Agarwal, George L Bakris, et al.
Cardiovascular Diabetology|March 16, 2018
Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA<sup>®</sup>): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal riskJulio Rosenstock, Vlado Perkovic, John H Alexander, et al.
Journal of Medical Genetics|February 14, 2018
Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort studyMaarten Arends, Marieke Biegstraaten, Christoph Wanner, et al.
Pageof 67